Kryptos Biotechnologies

Kryptos Biotechnologies is a biotechnology company that develops innovative diagnostic and life science solutions for complex diseases, focusing on single-cell analysis and point-of-care infectious disease diagnostics. The company has developed an integrated sample-to-answer PCR molecular diagnostic system that provides results in 25 minutes with accuracy comparable to laboratory systems, designed for decentralized clinical settings and on-site screening of asymptomatic persons. Their technology platform combines advanced analytical performance with proprietary science to examine DNA, RNA, and protein markers at the individual cell level, enabling insights into disease drivers and biological pathways. The company approach emphasizes that each cell is unique and possesses diverse clues about biological behavior, supporting educated clinical decisions through multi-omic analysis. Founded in 2017 and headquartered in Hayward, California, Kryptos Biotechnologies has raised $12.7 million in Series A funding from investors including FuturePlay, Coolidge Corner Investment, KBD Capital, OSANG Healthcare, and Berkeley SkyDeck.